Alfresa Holdings Corporation
ALFRY
Other OTC13.55
USD
- -
- -
ISIN
US0155091020
CUSIP
015509102
Return %
Stock
S&P500
1Y
-15.26
15.98
3Y
0.97
62.25
5Y
-41.97
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ryuji Arakawa
- Full Time Employees
- 12,525
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 1-1-3 Otemachi Tokyo TY Japan 100-0004
- IPO Date
- Jan 3, 2018
- Website
- alfresa.com
- Similar Companies
- Business
- Alfresa Holdings Corporation, established in 2003 and headquartered in Tokyo, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import, and export of pharmaceuticals, diagnostic reagents, medical devices, and related equipment; it operates dispensing pharmacies and supports Japan's healthcare supply chain as the nation's leading ethical pharmaceuticals wholesaler. The company operates through key segments including Ethical Pharmaceuticals Wholesaling, which delivers prescription drugs, diagnostic reagents, medical devices, equipment, and materials to hospitals, clinics, and pharmacies via a nationwide network of distribution centers; Self-Medication Products Wholesaling, offering over-the-counter drugs, health foods, and supplements to drugstores as a total healthcare merchandising wholesaler; Manufacturing, producing active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices at facilities compliant with GMP and QMS standards, including contract manufacturing; Dispensing Pharmacy and Related Businesses, providing community-based family pharmacy services with home healthcare support; Regenerative Medicine–Related Business, encompassing cell material supply, specified cell-processed products, and CMO/CDMO services; Overseas Business through joint ventures in China and Vietnam for pharmaceuticals, medical devices, and reagents; and other operations such as SPD services, CRO, and PMS. Alfresa Holdings maintains extensive geographic operations across Japan with over 200 distribution bases, 177 dispensing pharmacies, and production sites including plants in Okayama, Gunma, Akita, and Osaka; internationally, it focuses on Asia via entities like REMEJE PHARMACEUTICALS (CHINA) CO., LTD. and Alfresa Codupha Healthcare Vietnam Co., Ltd. Recent developments include a March 2025 business alliance and memorandum of understanding with Minaris Regenerative Medicine and Cell Resources Corporation to enhance cell therapy development, manufacturing, and distribution capabilities; a January 2025 capital and business alliance with GEXVal Inc., securing JPY 300 million to accelerate clinical development of GXV-001 and improve pharmaceutical access; a January 2025 share acquisition and alliance with Medley Inc. via Alfresa Corporation to advance digital transformation and electronic medication records for pharmacies; a November 2025 basic business alliance with KeyPharma Inc. for exclusive transportation and distribution rights of KP8011, a subacute spinal cord injury treatment; a strategic partnership with HekaBio to expand biopharma and medtech portfolios in CNS and regenerative medicine; and a December 2025 pact with CMIC Holdings to build a vaccination support platform. In April 2025, the company launched its 25-27 Mid-term Management Plan, Vision 2032 Stage 2, emphasizing total supply chain services expansion, growth investments in regenerative medicine and health tech, core business strengthening, and sustainability to target net sales of JPY 3,330 billion by fiscal 2027 and JPY 4 trillion by 2032.